{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:22:39Z","timestamp":1785824559133,"version":"3.56.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T00:00:00Z","timestamp":1720828800000},"content-version":"vor","delay-in-days":194,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.prdoa.2024.100264","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T19:05:16Z","timestamp":1720983916000},"page":"100264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Apomorphine titration with and without anti-emetic pretreatment in patients with Parkinson\u2019s disease experiencing OFF episodes: A modified Delphi panel"],"prefix":"10.1016","volume":"11","author":[{"given":"Stuart H.","family":"Isaacson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dewey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kremens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Ondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Pagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prdoa.2024.100264_b0005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1054-3589(08)60482-2","article-title":"Pharmacology and neurochemistry of apomorphine","volume":"15","author":"Di Chiara","year":"1978","journal-title":"Adv Pharmacol Chemother"},{"issue":"1","key":"10.1016\/j.prdoa.2024.100264_b0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1574886311308010009","article-title":"Domperidone in Parkinson's disease: a perilous arrhythmogenic or the gold standard?","volume":"8","author":"Lertxundi","year":"2013","journal-title":"Curr Drug Saf"},{"issue":"9","key":"10.1016\/j.prdoa.2024.100264_b0015","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/archneur.58.9.1385","article-title":"A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events","volume":"58","author":"Dewey","year":"2001","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.prdoa.2024.100264_b0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1474-4422(19)30396-5","article-title":"Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study","volume":"19","author":"Olanow","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.prdoa.2024.100264_b0025","unstructured":"ASHP, Drug Shortage Detail: Trimethobenzamide Capsules. Available at https:\/\/www.ashp.org\/drug-shortages\/current-shortages\/drug-shortage-detail.aspx?id=711. Last accessed May 2024., (2023)."},{"issue":"5","key":"10.1016\/j.prdoa.2024.100264_b0030","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.parkreldis.2012.01.001","article-title":"Apomorphine injections: predictors of initial common adverse events and long term tolerability","volume":"18","author":"Ondo","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"10.1016\/j.prdoa.2024.100264_b0035","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.parkreldis.2014.04.008","article-title":"Sustained efficacy of apomorphine in Japanese patients with advanced Parkinson's disease","volume":"20","author":"Hattori","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.prdoa.2024.100264_b0040","unstructured":"APOKYN\u00ae (apomorphine hydrochloride injection), for subcutaneous use. Prescribing information 2022. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/021264s022lbl.pdf. Accessed May 2024."},{"key":"10.1016\/j.prdoa.2024.100264_b0045","unstructured":"KYNMOBI\u2122 (apomorphine hydrochloride) sublingual film. Prescribing information. Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/210875lbl.pdf."},{"key":"10.1016\/j.prdoa.2024.100264_b0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JHL.S352500","article-title":"An Adaptation of the RAND\/UCLA Modified Delphi Panel Method in the Time of COVID-19","volume":"14","author":"Broder","year":"2022","journal-title":"J Healthc Leadersh"},{"issue":"9","key":"10.1016\/j.prdoa.2024.100264_b0055","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","article-title":"Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"17","author":"Katzenschlager","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.prdoa.2024.100264_b0060","doi-asserted-by":"crossref","unstructured":"R.A. Hauser, S. Isaacson, T. Clinch, I. Tigan\/Apokyn Study, Randomized, placebo-controlled trial of trimethobenzamide to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection, Parkinsonism Relat Disord 20(11) (2014) 1171-6.","DOI":"10.1016\/j.parkreldis.2014.08.010"},{"issue":"8123","key":"10.1016\/j.prdoa.2024.100264_b0065","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S0140-6736(79)91725-2","article-title":"Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease","volume":"1","author":"Corsini","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.prdoa.2024.100264_b0070","article-title":"How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature","volume":"8","author":"Isaacson","year":"2023","journal-title":"Clin Park Relat Disord"}],"container-title":["Clinical Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112524000355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112524000355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T11:01:30Z","timestamp":1734606090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112524000355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":14,"alternative-id":["S2590112524000355"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2024.100264","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apomorphine titration with and without anti-emetic pretreatment in patients with Parkinson\u2019s disease experiencing OFF episodes: A modified Delphi panel","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2024.100264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100264"}}